---
title: A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
nct_id: NCT04911751
overall_status: COMPLETED
phase: PHASE2
sponsor: KoBioLabs
study_type: INTERVENTIONAL
primary_condition: Psoriatic Plaque
countries: United States, Australia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04911751.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04911751"
ct_last_update_post_date: 2025-01-07
last_seen_at: "2026-05-12T07:09:24.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

**Official Title:** A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

**NCT ID:** [NCT04911751](https://clinicaltrials.gov/study/NCT04911751)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 80
- **Lead Sponsor:** KoBioLabs
- **Conditions:** Psoriatic Plaque
- **Start Date:** 2021-11-08
- **Completion Date:** 2024-10-07
- **CT.gov Last Update:** 2025-01-07

## Brief Summary

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Male or female, aged 18 to 75 years (inclusive)
* Have a diagnosis of plaque type psoriasis for ≥ 6 months
* Must have chronic plaque type psoriasis of moderate severity
* All subjects must agree and commit to the use of a reliable contraceptive regimen.

Exclusion Criteria:

* Current diagnosis of forms of psoriasis other than chronic plaque type only
* Drug-induced psoriasis
* Other inflammatory skin disease that may confound the evaluation of plaque psoriasis
* Failed 2 or more systemic treatments for plaque psoriasis
* Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit
```

## Arms

- **Low dose group** (EXPERIMENTAL) — 39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
- **High dose group** (EXPERIMENTAL) — 39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.

## Interventions

- **KBL697** (DRUG) — 1 capsule BID of KBL697 or Placebo
- **KBL697** (DRUG) — 5 capsules BID of KBL697 or Placebo

## Primary Outcomes

- **Psoriasis Area and Severity Index (PASI)** _(time frame: Baseline to Week 12)_ — Change from Baseline in PASI score

## Secondary Outcomes

- **Psoriasis Area and Severity Index (PASI)** _(time frame: Baseline to Weeks 2, 4 and 8)_
- **Psoriasis Area and Severity Index (PASI) -50** _(time frame: Baseline to Week 12)_
- **Psoriasis Area and Severity Index (PASI) -75** _(time frame: Baseline to Week 12)_
- **Physician's Global Assessment (PGA)** _(time frame: Baseline to Weeks 4, 8 and 12)_
- **Physician's Global Assessment (PGA)** _(time frame: Week 12)_
- **Psoriasis-Affected Body Surface Area (BSA)** _(time frame: Baseline to Weeks 4, 8 and 12)_
- **Safety measure through incidence of treatment-emergent adverse events (TEAEs)** _(time frame: Baseline to Week 16)_

## Locations (10)

- Total Skin and Beauty Dermatology Center, Birmingham, Alabama, United States
- Southern California Dermatology, Inc, Santa Ana, California, United States
- Clinical Science Institute, Santa Monica, California, United States
- Revival Research Institute, Doral, Florida, United States
- Indago Research and Health Center, Hialeah, Florida, United States
- Louisiana Dermatology Associates - Dermatology, Baton Rouge, Louisiana, United States
- Premier Specialist, Kogarah, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- Veracity Clinical Trials Ltd, Woolloongabba, Queensland, Australia
- Sinclair Dermatology, East Melbourne, Victoria, Australia

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.total skin and beauty dermatology center|birmingham|alabama|united states` — added _(2026-05-12)_
- `locations.southern california dermatology, inc|santa ana|california|united states` — added _(2026-05-12)_
- `locations.clinical science institute|santa monica|california|united states` — added _(2026-05-12)_
- `locations.revival research institute|doral|florida|united states` — added _(2026-05-12)_
- `locations.indago research and health center|hialeah|florida|united states` — added _(2026-05-12)_
- `locations.louisiana dermatology associates - dermatology|baton rouge|louisiana|united states` — added _(2026-05-12)_
- `locations.premier specialist|kogarah|new south wales|australia` — added _(2026-05-12)_
- `locations.westmead hospital|westmead|new south wales|australia` — added _(2026-05-12)_
- `locations.veracity clinical trials ltd|woolloongabba|queensland|australia` — added _(2026-05-12)_
- `locations.sinclair dermatology|east melbourne|victoria|australia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04911751.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04911751*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*